← All claims

Metabolic & Cardiometabolic · Gut & Microbiome

metabolic endotoxemia (LPS) causes GLP-1 resistance

In plain terms: Does gut inflammation blunt the appetite/blood-sugar hormone GLP-1?

Leans support Metabolic & Cardiometabolic 🐭 Non-human evidence🔬 Includes disconfirming
RefutedContestedStrong support
consensus score 0.44

Probably modestly yes — inflammation seems to dampen the hormone's signal, but this is shown mainly in animals and the lab.

📅 Last reviewed: 2026-07-15

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: Animal studies (Animal)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

7 support 2 contradict 0 tested null 4 mixed · 13 sources, 9 independent groups

What the evidence shows

Inflammation/LPS blunts GLP-1 signaling two ways: impaired FXR/TGR5-mediated secretion, and GLP-1-RECEPTOR silencing via promoter hypermethylation (DNMT3A/3B). 'GLP-1 resistance' is ligand- and receptor-side. Animal/mechanism-grade.

The evidence (13)

SourceGradeStanceQualityFinding
Deng et al.
2026 · Biochem Pharmacol
in-vitro supports moderate [FT-verified] LPS->DNMT3->GLP-1R promoter hypermethylation->reduced receptor (resistance mechanism)
⚠️ correction-on-file (Crossref) - kept, corrigendum not retraction
Cani
2007 · Diabetes
animal supports high Foundational: metabolic endotoxemia (LPS infusion/HFD) initiates obesity and insulin resistance and disrupts the gut-incretin metabolic milieu in mice
Balogun O et al
2026 · Nutrients
animal supports moderate Rodent (HFD-fed mice) model: quercetin restored intestinal barrier integrity, reducing plasma LPS by 36% and increasing GLP-1 by 23% versus HFD-alone controls. Shows an inverse LPS-GLP-1 relationship consistent with LPS suppressing GLP-1 se
Kishida
2017 · J Gastroenterol
animal mixed low Miglitol increased GLP-1 and suppressed endotoxemia in NASH model; reciprocal link supports endotoxemia impairing the GLP-1 axis
Ahn
2017 · Diabetes Obes Metab
RCT mixed moderate DPP4 inhibitor gemigliptin reduced postprandial ApoB48 in T2DM but whether systemic endotoxin is lowered remained inconclusive
Long et al.
2026 · Front Endocrinol
mechanism mixed low Endotoxemia -> impaired FXR/TGR5-mediated GLP-1 secretion (gut-immune-metabolic axis)
Nakamori
2024 · J Physiol
animal contradicts moderate Luminal LPS stimulates GLP-1 release from colonic L cells via TLR4 (LPS raises, not blunts, GLP-1)
Anhe
2021 · Cell Rep
animal supports high Metabolic endotoxemia effect dictated by LPS lipid-A acylation; LPS structure drives inflammatory/metabolic (incl incretin-axis) dysfunction in obese mice
Wongkrasant
2020 · J Pharmacol Sci
animal supports moderate Intestinal inflammation drove L-cell apoptosis via NF-kB-iNOS-caspase-3 lowering GLP-1; FOS rescued GLP-1 levels, evidencing inflammation-impaired GLP-1
Lebrun
2017 · Cell Rep
animal contradicts moderate [FT-verified] acute LPS RAISES GLP-1 via TLR4 (mice+humans) - opposite of secretory resistance
Zong
2022 · Int J Mol Sci
animal mixed low Salmonella/endotoxin lowers blood GLP-1 by triggering enteroendocrine L-cell pyroptosis
Oh
2015 · Obes Surg
animal supports moderate Ileal transposition lowered plasma LPS and raised L-cell secretion with improved insulin sensitivity, implying endotoxemia suppresses GLP-1 output
Wang
2023 · Nat Metab
animal supports high Total parenteral nutrition altered gut microbiota/metabolites impairing glucose metabolism; a GLP-1 receptor agonist fully prevented the disorder

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.